HBV and HCV serological monitoring among injection drugs users in opiate substitution treatment in Bosnia and Herzegovina

Sinisa Skocibusic; Marko Martinac; Jurica Arapovic; Svjetlana Grgic; Jadranka Nikolic; Dino Hasanagic; Milenko Bevanda; Jelena Ravlija

doi:10.3855/jidc.7445

HBV and HCV serological monitoring among injection drugs users in opiate substitution treatment in Bosnia and Herzegovina

Authors

Sinisa Skocibusic Clinic for Infectious Diseases, University Hospital Mostar, Mostar, Bosnia and Herzegovina
Marko Martinac Faculty of Medicine, University of Mostar, Mostar, Bosnia and Herzegovina
Jurica Arapovic Clinic for Infectious Diseases, University Hospital Mostar, Mostar, Bosnia and Herzegovina
Svjetlana Grgic Clinic for Infectious Diseases, University Hospital Mostar, Mostar, Bosnia and Herzegovina
Jadranka Nikolic Clinic for Infectious Diseases, University Hospital Mostar, Mostar, Bosnia and Herzegovina
Dino Hasanagic Faculty of Natural Sciences and Mathematics, University of Banja Luka, Banja Luka, Bosnia and Herzegovina
Milenko Bevanda Faculty of Medicine, University of Mostar, Mostar, Bosnia and Herzegovina
Jelena Ravlija Faculty of Medicine, University of Mostar, Mostar, Bosnia and Herzegovina

DOI:

https://doi.org/10.3855/jidc.7445

Keywords:

prevalence, risk factors, hepatitis B virus, hepatitis C virus, drug users, opiate substitution treatment

Abstract

Introduction: Use of intravenous heroin carries a risk of serious medical conditions, including acquiring blood-borne infections. Therefore, hepatitis B virus (HBV) and hepatitis C virus (HCV) infection represent a threat for people who inject drugs (PWID). The objectives of this study were to determine the extent and characteristics of risk factors for acquiring HBV and HCV infection in PWID included in opiate substitution treatment in the southern part of Bosnia and Herzegovina (B&H).

Methodology: The study included 120 adult PWID of both sexes who participated in opiate substitution treatment. All participants were interviewed, and their blood samples were tested for the presence of the surface hepatitis B virus antigen (HBsAg) and hepatitis C virus antibodies (anti-HCV). Prevalence data were obtained and compared to the serological status.

Results: HBsAg prevalence among PWID was 0.8% (1/120), whereas seroprevalence of anti-HCV was 52.5% (63/120). PWID exposed to risk-behavior factors (such as unsafe sexual activity, serving prison sentence, and tattooing) were more frequently anti-HCV positive.Sharing drug paraphernalia was found to be the most significant risk factor. The highest predictive values for acquiring HCV-infection were attributed to PWID who used heroin for more than three years and who were unmarried.

Conclusions: HBsAg prevalence among PWID is rare (0.8%), while HCV-infection (52.5%) presents an important health and social issue among PWID in B&H. Sharing drug paraphernalia and intravenous heroin use longer than three years were the most prominent risk-behavior factors among the patients we investigated.

Author Biography

Sinisa Skocibusic, Clinic for Infectious Diseases, University Hospital Mostar, Mostar, Bosnia and Herzegovina

MD, MSc

ID specialist

Downloads

Published

2016-09-30

How to Cite

Skocibusic S, Martinac M, Arapovic J, Grgic S, Nikolic J, Hasanagic D, Bevanda M, Ravlija J (2016) HBV and HCV serological monitoring among injection drugs users in opiate substitution treatment in Bosnia and Herzegovina. J Infect Dev Ctries 10:968–972. doi: 10.3855/jidc.7445

Download Citation

Endnote/Zotero/Mendeley (RIS)

Issue

Vol. 10 No. 09: September 2016

Section

Original Articles

License

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).